Safety and Efficacy of Ultrasound-Enhanced Thrombolysis A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies

Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcrania...

Full description

Saved in:
Bibliographic Details
Published inStroke (1970) Vol. 41; no. 2; pp. 280 - 287
Main Authors Tsivgoulis, Georgios, Eggers, Jürgen, Ribo, Marc, Perren, Fabienne, Saqqur, Maher, Rubiera, Marta, Sergentanis, Theodoros N., Vadikolias, Konstantinos, Larrue, Vincent, Molina, Carlos A., Alexandrov, Andrei V.
Format Journal Article
LanguageEnglish
Published Hagerstown, MD Lippincott Williams & Wilkins 01.02.2010
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA). Subjects and Methods— Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD±microspheres (μS), tPA+TCCD±μS, and tPA+low-frequency ultrasound. Results— A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%–11.2%); tPA+TCCD, 11.1% (95% CI, 0%–28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%– 61.4%); and tPA alone, 2.9% (95% CI, 0%–8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%– 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%–24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD±μS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70–5.25; P =0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44–3.60; P =0.67). Conclusions— The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.
AbstractList Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA).BACKGROUND AND PURPOSEUltrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA).Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound.SUBJECTS AND METHODSThrough Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound.A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67).RESULTSA total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67).The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.CONCLUSIONSThe present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.
Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA). Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD+/-microspheres (microS), tPA+TCCD+/-microS, and tPA+low-frequency ultrasound. A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%-11.2%); tPA+TCCD, 11.1% (95% CI, 0%-28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%- 61.4%); and tPA alone, 2.9% (95% CI, 0%-8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%- 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%-24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD+/-microS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70-5.25; P=0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44-3.60; P=0.67). The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.
Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound technologies were used to increase the thrombolytic activity of tissue plasminogen activator (tPA), including transcranial Doppler (TCD), transcranial color-coded duplex (TCCD), and low-frequency ultrasound. We performed a meta-analysis to evaluate the safety and efficacy of ultrasound-enhanced thrombolysis compared to the current standard of care (intravenous tPA). Subjects and Methods— Through Medline, Embase, and Cochrane database search, we identified and abstracted all studies of ultrasound-enhanced thrombolysis in acute cerebral ischemia. Principal investigators were contacted if data not available through peer-reviewed publication were needed. Symptomatic intracerebral hemorrhage (sICH) and recanalization rates were compared between tPA, tPA+TCD±microspheres (μS), tPA+TCCD±μS, and tPA+low-frequency ultrasound. Results— A total of 6 randomized (n=224) and 3 nonrandomized (n=192) studies were identified. The rates of symptomatic intracerebral hemorrhage in randomized studies were as follows: tPA+TCD, 3.8% (95% CI, 0%–11.2%); tPA+TCCD, 11.1% (95% CI, 0%–28.9%); tPA+low-frequency ultrasound, 35.7% (95% CI, 16.2%– 61.4%); and tPA alone, 2.9% (95% CI, 0%–8.4%). Complete recanalization rates were higher in patients receiving combination of TCD with tPA 37.2% (95% CI, 26.5%– 47.9%) compared with patients treated with tPA alone 17.2% (95% CI, 9.5%–24.9%). In 8 trials of high-frequency (TCD/TCCD) ultrasound-enhanced thrombolysis, tPA+TCD/TCCD±μS was associated with a higher likelihood of complete recanalization (pooled OR, 2.99; 95% CI, 1.70–5.25; P =0.0001) when compared to tPA alone. High-frequency ultrasound-enhanced thrombolysis was not associated with an increased risk of symptomatic intracerebral hemorrhage (pooled OR, 1.26; 95% CI, 0.44–3.60; P =0.67). Conclusions— The present safety and signal-of-efficacy data of high-frequency ultrasound-enhanced thrombolysis should be taken into account in the design of future randomized controlled trials.
Author Larrue, Vincent
Rubiera, Marta
Ribo, Marc
Sergentanis, Theodoros N.
Vadikolias, Konstantinos
Alexandrov, Andrei V.
Perren, Fabienne
Eggers, Jürgen
Tsivgoulis, Georgios
Molina, Carlos A.
Saqqur, Maher
Author_xml – sequence: 1
  givenname: Georgios
  surname: Tsivgoulis
  fullname: Tsivgoulis, Georgios
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 2
  givenname: Jürgen
  surname: Eggers
  fullname: Eggers, Jürgen
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 3
  givenname: Marc
  surname: Ribo
  fullname: Ribo, Marc
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 4
  givenname: Fabienne
  surname: Perren
  fullname: Perren, Fabienne
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 5
  givenname: Maher
  surname: Saqqur
  fullname: Saqqur, Maher
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 6
  givenname: Marta
  surname: Rubiera
  fullname: Rubiera, Marta
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 7
  givenname: Theodoros N.
  surname: Sergentanis
  fullname: Sergentanis, Theodoros N.
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 8
  givenname: Konstantinos
  surname: Vadikolias
  fullname: Vadikolias, Konstantinos
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 9
  givenname: Vincent
  surname: Larrue
  fullname: Larrue, Vincent
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 10
  givenname: Carlos A.
  surname: Molina
  fullname: Molina, Carlos A.
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
– sequence: 11
  givenname: Andrei V.
  surname: Alexandrov
  fullname: Alexandrov, Andrei V.
  organization: From Comprehensive Stroke Center (G.T., A.V.A.), Department of Neurology, University of Alabama at Birmingham Hospital, Birmingham, Ala; Department of Neurology (G.T., K.V.), Democritus University of Thrace School of Medicine, Alexandroupolis, Greece; Department of Neurology (J.E.), Asklepios Hospital North, Hamburg, Germany; Department of Neurology (M. Rubiera, M. Ribo, C.A.M.), Hospital Universitari Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain; Department of Neurology (F.P.)
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22368174$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/20044531$$D View this record in MEDLINE/PubMed
BookMark eNp9kd1LwzAUxYNM3If-ByJ9EZ8689U08W2M6sTBwG3PIU0TVumambQP_e-tbFPwwacLl9853HPPGAxqVxsAbhGcIsTQ43rzvnrLZovZFEExTRghkF6AEUowjSnDfABGEBIRYyrEEIxD-IAQYsKTKzDEEFKaEDQC6VpZ03SRqosos7bUSneRs9G2arwKrq2LOKt3qtamiDY77_a5q7pQhmtwaVUVzM1pTsD2OdvMF_Fy9fI6ny1jTVLUxELkkOuEUGtQkguuNaOUcqgNKliCOe_P1dpoSxBVuWLK5tDkKlWMQKF5Tibg4eh78O6zNaGR-zJoU1WqNq4NMiUUJylCuCfvTmSb700hD77cK9_Jc9YeuD8BKmhVWd-nKsMvhwnjKKU993TktHcheGOlLhvVlK7uX1JWEkH5XYD8KaDfCHksoBfTP-Kz_7-yL1y-iH0
CODEN SJCCA7
CitedBy_id crossref_primary_10_1080_14656566_2017_1309022
crossref_primary_10_1016_j_mayocp_2014_03_001
crossref_primary_10_31728_jnn_2020_00084
crossref_primary_10_1039_D2RA04467F
crossref_primary_10_1161_STROKEAHA_120_030960
crossref_primary_10_1586_ern_11_3
crossref_primary_10_1016_j_ejvs_2013_05_019
crossref_primary_10_1002_14651858_CD000514_pub3
crossref_primary_10_1111_jth_12321
crossref_primary_10_1177_2396987321989865
crossref_primary_10_1088_0031_9155_60_18_7403
crossref_primary_10_1186_s13089_018_0099_y
crossref_primary_10_3389_fneur_2014_00215
crossref_primary_10_1161_STROKEAHA_116_014181
crossref_primary_10_1002_jcu_21978
crossref_primary_10_3171_2011_10_FOCUS11251
crossref_primary_10_1177_154431671403800302
crossref_primary_10_1111_ijs_12536
crossref_primary_10_1186_s43162_025_00419_8
crossref_primary_10_1016_j_jvir_2010_10_007
crossref_primary_10_1186_1477_7819_12_301
crossref_primary_10_1097_RLI_0000000000000369
crossref_primary_10_1016_j_mtbio_2023_100556
crossref_primary_10_1248_bpb_b16_00702
crossref_primary_10_5692_clinicalneurol_50_547
crossref_primary_10_1007_s11239_012_0850_3
crossref_primary_10_1097_NRL_0b013e318236e041
crossref_primary_10_1038_s41598_020_69202_9
crossref_primary_10_1063_1_4973857
crossref_primary_10_7887_jcns_21_383
crossref_primary_10_1016_j_pcad_2015_03_005
crossref_primary_10_1016_j_jstrokecerebrovasdis_2014_06_018
crossref_primary_10_1007_s11936_015_0373_2
crossref_primary_10_1016_j_ijchv_2014_08_003
crossref_primary_10_1155_2013_629378
crossref_primary_10_1371_journal_pone_0168909
crossref_primary_10_7863_ultra_15_11018
crossref_primary_10_1186_s12883_015_0359_4
crossref_primary_10_3389_fphar_2015_00197
crossref_primary_10_1038_srep16026
crossref_primary_10_1016_S1474_4422_19_30026_2
crossref_primary_10_1007_s11239_010_0483_3
crossref_primary_10_3171_2019_9_FOCUS19624
crossref_primary_10_1586_14737175_2014_934676
crossref_primary_10_1186_s13063_016_1754_x
crossref_primary_10_1053_j_tvir_2011_12_002
crossref_primary_10_1111_jon_12026
crossref_primary_10_1007_s12975_014_0332_3
crossref_primary_10_1016_j_neuarg_2012_02_002
crossref_primary_10_1016_j_ajem_2019_03_003
crossref_primary_10_1111_ane_12861
crossref_primary_10_1093_brain_awt201
crossref_primary_10_1016_j_ejvs_2010_11_035
crossref_primary_10_1039_C7RA08971F
crossref_primary_10_1080_10717544_2021_1879315
crossref_primary_10_1109_TUFFC_2015_007016
crossref_primary_10_3109_02656736_2012_674621
crossref_primary_10_1056_NEJMct1007370
crossref_primary_10_3109_02656736_2012_678029
crossref_primary_10_1002_jum_16611
crossref_primary_10_1016_j_permed_2012_02_022
crossref_primary_10_1016_j_permed_2012_02_023
crossref_primary_10_15420_ecr_2019_6_1
crossref_primary_10_1159_000365555
crossref_primary_10_1016_j_ultrasmedbio_2014_12_006
crossref_primary_10_3171_2012_10_JNS12449
crossref_primary_10_1016_j_thromres_2015_08_027
crossref_primary_10_1016_j_wneu_2011_05_048
crossref_primary_10_1177_1756286419860652
crossref_primary_10_1371_journal_pone_0152898
crossref_primary_10_3171_2017_11_FOCUS17608
crossref_primary_10_3346_jkms_2018_33_e279
crossref_primary_10_1007_s11670_012_0277_6
crossref_primary_10_3390_brainsci13050840
crossref_primary_10_1109_TUFFC_2015_007268
crossref_primary_10_1007_s11936_012_0176_7
crossref_primary_10_1002_brb3_279
crossref_primary_10_1097_RLI_0000000000000059
crossref_primary_10_1073_pnas_2003569117
crossref_primary_10_1517_17530059_2010_495749
crossref_primary_10_1080_1061186X_2017_1365874
crossref_primary_10_1212_WNL_0b013e31826958d3
crossref_primary_10_1111_j_1552_6569_2011_00632_x
crossref_primary_10_1016_j_ijcard_2018_05_101
crossref_primary_10_1111_ijs_12340
crossref_primary_10_1371_journal_pone_0210516
crossref_primary_10_1016_j_otc_2010_08_003
crossref_primary_10_1097_MD_0000000000003615
crossref_primary_10_1007_s11940_012_0214_5
crossref_primary_10_1016_S1773_2247_12_50065_1
crossref_primary_10_3892_ol_2015_3509
crossref_primary_10_1038_jcbfm_2011_127
crossref_primary_10_1111_j_1538_7836_2011_04371_x
crossref_primary_10_2214_AJR_14_13632
crossref_primary_10_1586_14779072_2015_1075882
crossref_primary_10_1186_1745_6215_12_20
crossref_primary_10_1016_j_ultrasmedbio_2016_03_027
crossref_primary_10_1088_0031_9155_57_15_4951
crossref_primary_10_1161_STROKEAHA_116_014644
crossref_primary_10_1371_journal_pone_0177786
crossref_primary_10_1038_nrneurol_2011_89
crossref_primary_10_3171_2017_11_FOCUS17586
crossref_primary_10_1016_j_eururo_2012_02_019
crossref_primary_10_1016_j_wem_2010_10_007
crossref_primary_10_1586_erc_12_35
crossref_primary_10_1021_acs_bioconjchem_9b00653
crossref_primary_10_31728_jnn_2019_00046
crossref_primary_10_1586_erd_12_88
crossref_primary_10_1080_14712598_2016_1227779
crossref_primary_10_1016_j_permed_2012_02_038
crossref_primary_10_1016_j_fmc_2016_04_005
crossref_primary_10_1155_2017_7021929
crossref_primary_10_1177_2040622310394032
crossref_primary_10_1016_j_emc_2016_06_009
crossref_primary_10_1002_jmri_24451
crossref_primary_10_1007_s15005_019_0068_4
crossref_primary_10_1161_JAHA_115_002716
crossref_primary_10_1016_j_ultrasmedbio_2021_08_017
crossref_primary_10_1016_j_cult_2011_12_008
crossref_primary_10_1016_j_jocn_2018_10_001
crossref_primary_10_7863_ultra_32_7_1117
crossref_primary_10_1177_154431671503900402
crossref_primary_10_1186_s13231_014_0014_y
crossref_primary_10_1088_0031_9155_60_19_7695
crossref_primary_10_1007_s12975_011_0080_6
crossref_primary_10_1016_j_brs_2011_03_007
crossref_primary_10_1007_s11051_025_06282_6
crossref_primary_10_1109_TUFFC_2013_2615
Cites_doi 10.1161/strokeaha.107.505594
10.1056/NEJMoa041175
10.1161/01.str.0000199064.94588.39
10.1161/STROKEAHA.108.530931
10.1111/j.1552-6569.2004.tb00226.x
10.1016/j.ultras.2007.11.008
10.1002/9780470773666
10.1016/0041-624X(91)90030-C
10.1161/01.str.0000140890.86779.79
10.1161/01.str.0000221813.27519.0b
10.1136/bmj.327.7414.560
10.1161/circ.98.10.1030
10.1161/strokeaha.107.503870
10.1016/j.ultrasmedbio.2005.03.008
10.1161/str.19.5.3363593
10.1161/01.STR.0000254524.23708.c9
10.1161/01.str.0000258112.14918.24
10.1182/blood.V81.10.2636.2636
10.1002/ana.21723
10.1016/0301-5629(94)00119-X
10.1161/strokeaha.107.505727
10.1161/01.str.0000170707.86793.1a
10.1002/ana.10590
ContentType Journal Article
Copyright 2015 INIST-CNRS
Copyright_xml – notice: 2015 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/STROKEAHA.109.563304
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4628
EndPage 287
ExternalDocumentID 20044531
22368174
10_1161_STROKEAHA_109_563304
Genre Meta-Analysis
Journal Article
Review
GroupedDBID ---
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
123
1J1
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5RE
5VS
6PF
71W
77Y
7O~
A9M
AAAAV
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AAQQT
AARTV
AASCR
AASOK
AAUEB
AAXQO
AAYEP
AAYJJ
AAYXX
ABASU
ABBUW
ABDIG
ABJNI
ABPXF
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACDOF
ACEWG
ACGFS
ACGOD
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADGHP
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFDTB
AFEXH
AFFNX
AFMBP
AFNMH
AFSOK
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
AYCSE
BAWUL
BCGUY
BOYCO
BQLVK
BS7
C45
CITATION
CS3
DIK
DIWNM
DU5
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
J5H
JF9
JG8
JK3
JK8
K8S
KD2
KMI
KQ8
L-C
L7B
M18
N4W
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB3
OCUKA
ODA
ODMTH
OGROG
OHYEH
OK1
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OVOZU
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YHZ
YQJ
YYP
ZB8
ZGI
ZZMQN
IQODW
ACIJW
CGR
CUY
CVF
ECM
EIF
NPM
YCJ
7X8
ID FETCH-LOGICAL-c371t-99b08c534fe15b98cc644480ce1d65288152ccecf314aba6afb0eba7a6309c8b3
ISSN 0039-2499
1524-4628
IngestDate Fri Jul 11 10:27:08 EDT 2025
Thu Apr 03 06:56:22 EDT 2025
Mon Jul 21 09:13:57 EDT 2025
Tue Jul 01 03:03:47 EDT 2025
Thu Apr 24 23:08:52 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Doppler ultrasound study
sonothrombolysis
Stroke
Nervous system diseases
Serine endopeptidases
tissue plasminogen activator
Enzyme
Color
Cardiovascular disease
t-Plasminogen activator
Cerebral disorder
Vascular disease
transcranial color-coded duplex
Peptidases
transcranial Doppler
Central nervous system disease
Hydrolases
Ultrasound
ultrasound-enhancedthrombolysis
Cerebrovascular disease
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c371t-99b08c534fe15b98cc644480ce1d65288152ccecf314aba6afb0eba7a6309c8b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 20044531
PQID 734257112
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_734257112
pubmed_primary_20044531
pascalfrancis_primary_22368174
crossref_citationtrail_10_1161_STROKEAHA_109_563304
crossref_primary_10_1161_STROKEAHA_109_563304
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2010-02-01
PublicationDateYYYYMMDD 2010-02-01
PublicationDate_xml – month: 02
  year: 2010
  text: 2010-02-01
  day: 01
PublicationDecade 2010
PublicationPlace Hagerstown, MD
PublicationPlace_xml – name: Hagerstown, MD
– name: United States
PublicationTitle Stroke (1970)
PublicationTitleAlternate Stroke
PublicationYear 2010
Publisher Lippincott Williams & Wilkins
Publisher_xml – name: Lippincott Williams & Wilkins
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_21_2
e_1_3_2_22_2
e_1_3_2_23_2
e_1_3_2_24_2
e_1_3_2_25_2
(e_1_3_2_20_2) 2006; 1
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_1_2
(e_1_3_2_9_2) 2008; 25
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_2_2
(e_1_3_2_14_2) 1986; 17
(e_1_3_2_10_2) 2007; 38
References_xml – ident: e_1_3_2_3_2
  doi: 10.1161/strokeaha.107.505594
– ident: e_1_3_2_5_2
  doi: 10.1056/NEJMoa041175
– ident: e_1_3_2_6_2
  doi: 10.1161/01.str.0000199064.94588.39
– ident: e_1_3_2_1_2
  doi: 10.1161/STROKEAHA.108.530931
– ident: e_1_3_2_4_2
  doi: 10.1111/j.1552-6569.2004.tb00226.x
– ident: e_1_3_2_2_2
  doi: 10.1016/j.ultras.2007.11.008
– volume: 25
  start-page: 19
  year: 2008
  ident: e_1_3_2_9_2
  publication-title: J Thromb Thrombolysis
– ident: e_1_3_2_21_2
  doi: 10.1002/9780470773666
– ident: e_1_3_2_13_2
  doi: 10.1016/0041-624X(91)90030-C
– ident: e_1_3_2_16_2
  doi: 10.1161/01.str.0000140890.86779.79
– volume: 1
  start-page: 136
  year: 2006
  ident: e_1_3_2_20_2
  publication-title: J Usability Studies
– ident: e_1_3_2_27_2
  doi: 10.1161/01.str.0000221813.27519.0b
– ident: e_1_3_2_22_2
  doi: 10.1136/bmj.327.7414.560
– ident: e_1_3_2_24_2
  doi: 10.1161/circ.98.10.1030
– ident: e_1_3_2_11_2
  doi: 10.1161/strokeaha.107.503870
– ident: e_1_3_2_15_2
  doi: 10.1016/j.ultrasmedbio.2005.03.008
– ident: e_1_3_2_19_2
  doi: 10.1161/str.19.5.3363593
– ident: e_1_3_2_17_2
  doi: 10.1161/01.STR.0000254524.23708.c9
– ident: e_1_3_2_18_2
  doi: 10.1161/01.str.0000258112.14918.24
– volume: 38
  start-page: 472.
  year: 2007
  ident: e_1_3_2_10_2
  publication-title: Stroke
– ident: e_1_3_2_26_2
  doi: 10.1182/blood.V81.10.2636.2636
– ident: e_1_3_2_23_2
  doi: 10.1002/ana.21723
– ident: e_1_3_2_25_2
  doi: 10.1016/0301-5629(94)00119-X
– ident: e_1_3_2_7_2
  doi: 10.1161/strokeaha.107.505727
– ident: e_1_3_2_12_2
  doi: 10.1161/01.str.0000170707.86793.1a
– volume: 17
  start-page: 95
  year: 1986
  ident: e_1_3_2_14_2
  publication-title: Cardiovasc Clin
– ident: e_1_3_2_8_2
  doi: 10.1002/ana.10590
SSID ssj0002385
Score 2.3994842
SecondaryResourceType review_article
Snippet Background and Purpose— Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3...
Ultrasound-enhanced thrombolysis is a promising new approach to facilitate reperfusion therapies for acute ischemic stroke. So far, 3 different ultrasound...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 280
SubjectTerms Aged
Aged, 80 and over
Biological and medical sciences
Brain Ischemia - diagnostic imaging
Brain Ischemia - physiopathology
Brain Ischemia - therapy
Cardiovascular system
Combined Modality Therapy - adverse effects
Combined Modality Therapy - methods
Combined Modality Therapy - statistics & numerical data
Female
Fibrinolytic Agents - administration & dosage
Fibrinolytic Agents - adverse effects
Humans
Intracranial Thrombosis - diagnostic imaging
Intracranial Thrombosis - physiopathology
Intracranial Thrombosis - therapy
Male
Medical sciences
Middle Aged
Neurology
Pharmacology. Drug treatments
Randomized Controlled Trials as Topic - statistics & numerical data
Thrombolytic Therapy - adverse effects
Thrombolytic Therapy - methods
Thrombolytic Therapy - statistics & numerical data
Tissue Plasminogen Activator - administration & dosage
Tissue Plasminogen Activator - adverse effects
Treatment Outcome
Ultrasonic Therapy - adverse effects
Ultrasonic Therapy - methods
Ultrasonic Therapy - statistics & numerical data
Ultrasonography, Doppler, Transcranial - adverse effects
Ultrasonography, Doppler, Transcranial - methods
Ultrasonography, Doppler, Transcranial - statistics & numerical data
Vascular diseases and vascular malformations of the nervous system
Vasodilator agents. Cerebral vasodilators
Subtitle A Comprehensive Review and Meta-Analysis of Randomized and Nonrandomized Studies
Title Safety and Efficacy of Ultrasound-Enhanced Thrombolysis
URI https://www.ncbi.nlm.nih.gov/pubmed/20044531
https://www.proquest.com/docview/734257112
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BkRASQrwJj8oHenTwY3dtH6MoVdSqIEgi9WbtrnfTqCWuHIcDv54Z78Z2ITzKxbIs78r2jL95zxDy3pgwUgVjPpdM-1RL6mdMR76JmQRsFCYrsN757COfLujJOTvvvEpNdUkth-r73rqS_6EqXAO6YpXsLSjbbgoX4BzoC0egMBz_icYzYTDjEn3fE2wFgaPbQflbXNWV2OC8JH-yvrAh_vlFVX6VZdOApK-QzuqqvGz0zDBLgp5fYL5ZfVu249Ib1_mq7BTw5dINVzvZHo3HR2mKRZxt9GYlS1cIpDrsrSoLccdCNllmfYcDxsrb5A0HojEGZexco6F2uBlRH8tc-8BKwx4DRX2UtMObnMCNrMT9Fcs5Yvls_uXT6WQ0HWHjqyHj6H_pZNcuXv-TSGsTDRsTh4d5uwtG3HO7y11yLwLbAsdenH7uWsyDDmPHXri3dPWWsMuHfc9yQ595eC028GsZOxPl90ZLo7zMH5NHzurwRpaFnpA7ev2U3D9zeRXPSGI5yQNO8nac5JXG28NJXp-TnpPF8WQ-nvpupIav4iSs_SyTQapYTI0OmcxSpUAfpmmgdFhwFqUpEFIprUwcUiEFF0YGWopE8DjIVCrjF-RgXa71K-JJZhgvBKdBgQ2SYlBzAqp4YSiTCQD7gMS7D5Mr128ex55c5X8iyoD47apr22_lL_cf3vjm7SJQe3kK5vaAeDsi5ICcGA4Ta11uN3kSo7wCe2NAXlridIsxzwGk0-tbPs0b8qD7Y96Sg7ra6negtNbysGGyH6WLjnw
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+and+Efficacy+of+Ultrasound-Enhanced+Thrombolysis&rft.jtitle=Stroke+%281970%29&rft.au=Tsivgoulis%2C+Georgios&rft.au=Eggers%2C+Ju%CC%88rgen&rft.au=Ribo%2C+Marc&rft.au=Perren%2C+Fabienne&rft.date=2010-02-01&rft.issn=0039-2499&rft.eissn=1524-4628&rft.volume=41&rft.issue=2&rft.spage=280&rft.epage=287&rft_id=info:doi/10.1161%2FSTROKEAHA.109.563304&rft.externalDBID=n%2Fa&rft.externalDocID=10_1161_STROKEAHA_109_563304
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0039-2499&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0039-2499&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0039-2499&client=summon